Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.

Lu YF, Zhang Q, Chen HY, Chen JY, Pan Y, Xu CC, Xu JX, Yu RS.

Medicine (Baltimore). 2019 Jun;98(26):e16289. doi: 10.1097/MD.0000000000016289.

2.

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG.

BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

3.

New markers in prostate cancer: Genomics.

Fuessel S, Wirth MP.

Arch Esp Urol. 2019 Mar;72(2):116-125. Review.

PMID:
30855012
4.

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.

Aminsharifi A, Simon R, Polascik TJ, Robertson CN, Sudan DL, Collins BH, Moul JW.

J Urol. 2019 Sep;202(3):469-474. doi: 10.1097/JU.0000000000000207. Epub 2019 Aug 8. Review.

PMID:
30835631
5.

Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.

Pike LRG, Wu J, Chen MH, Loffredo M, Renshaw AA, Pfail J, Kantoff PW, D'Amico AV.

Urology. 2019 Apr;126:145-151. doi: 10.1016/j.urology.2018.11.056. Epub 2019 Jan 18.

PMID:
30664895
6.

Patient-Friendly Summary of the ACR Appropriateness Criteria: Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Andrews DB, Lalani T.

J Am Coll Radiol. 2019 Jan;16(1):e1. doi: 10.1016/j.jacr.2018.08.005. No abstract available.

PMID:
30611386
7.

Relevance of total PSA and free PSA prescriptions.

Lamy PJ, Brouillet JP, Bermont L, Fouillet G, Loric S.

Ann Biol Clin (Paris). 2018 Dec 1;76(6):659-663. doi: 10.1684/abc.2018.1392. Review.

PMID:
30543191
8.

Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.

Verbeek JFM, Bangma CH, Kweldam CF, van der Kwast TH, Kümmerlin IP, van Leenders GJLH, Roobol MJ.

Urol Oncol. 2019 Feb;37(2):138-144. doi: 10.1016/j.urolonc.2018.11.021. Epub 2018 Dec 7.

PMID:
30528698
9.

Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.

Li-Sheng Chen S, Ching-Yuan Fann J, Sipeky C, Yang TK, Yueh-Hsia Chiu S, Ming-Fang Yen A, Laitinen V, Tammela TLJ, Stenman UH, Auvinen A, Schleutker J, Chen HH.

J Urol. 2019 Mar;201(3):486-495. doi: 10.1016/j.juro.2018.10.015.

PMID:
30366021
10.

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

PMID:
30350010
11.

Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.

Mao Z, Ji A, Yang K, He W, Hu Y, Zhang Q, Zhang D, Xie L.

Medicine (Baltimore). 2018 Oct;97(42):e12806. doi: 10.1097/MD.0000000000012806.

12.

Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.

Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL.

Contrast Media Mol Imaging. 2018 Sep 19;2018:3181258. doi: 10.1155/2018/3181258. eCollection 2018.

13.

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R.

Clin Genitourin Cancer. 2019 Feb;17(1):e92-e96. doi: 10.1016/j.clgc.2018.09.013. Epub 2018 Sep 24.

PMID:
30327180
14.

Screening for Prostate Cancer: Recommendation Statement.

[No authors listed]

Am Fam Physician. 2018 Oct 15;98(8):Online. No abstract available.

PMID:
30277733
16.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.

Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.

17.

Novel Biomarkers for Prostate Cancer Detection and Prognosis.

Filella X, Foj L.

Adv Exp Med Biol. 2018;1095:15-39. doi: 10.1007/978-3-319-95693-0_2. Review.

PMID:
30229547
18.

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA.

Radiology. 2018 Dec;289(3):730-737. doi: 10.1148/radiol.2018180788. Epub 2018 Sep 18.

PMID:
30226456
19.

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.

Tikkinen KAO, Dahm P, Lytvyn L, Heen AF, Vernooij RWM, Siemieniuk RAC, Wheeler R, Vaughan B, Fobuzi AC, Blanker MH, Junod N, Sommer J, Stirnemann J, Yoshimura M, Auer R, MacDonald H, Guyatt G, Vandvik PO, Agoritsas T.

BMJ. 2018 Sep 5;362:k3581. doi: 10.1136/bmj.k3581. No abstract available.

20.

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.

Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P.

BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519.

Supplemental Content

Loading ...
Support Center